{"originalText": "规范临床医生合理选择改善糖尿病微循环障碍的药物,", "entities": [{"label_type": "Disease", "start_pos": 12, "end_pos": 20}]}
{"originalText": "GCKR_rs780094_与血清尿酸水平密_切相关._综上所述,本研究在新疆维吾尔族人群中进行了_GCKR_基因_rs780094_多态性与高尿酸血症之间的相关_性研究,并证实了_GCKR_基因_rs780094_A_等位基因是_高尿酸血症的危险因素,且携带_A_/_A、A_/_G_基因型患_高尿酸血症的危险是携带_G_/_G_基因型的_1._355_倍._这为揭示高尿酸血症的遗传异质性提供了一定的±_据,为今后在该人群中开展高尿酸血症的防治提供了_一定的参考._", "entities": [{"label_type": "Test", "start_pos": 17, "end_pos": 19}, {"label_type": "Anatomy", "start_pos": 50, "end_pos": 54}, {"label_type": "Disease", "start_pos": 71, "end_pos": 76}, {"label_type": "Anatomy", "start_pos": 91, "end_pos": 95}, {"label_type": "Disease", "start_pos": 116, "end_pos": 121}, {"label_type": "Disease", "start_pos": 148, "end_pos": 153}, {"label_type": "Disease", "start_pos": 185, "end_pos": 190}, {"label_type": "Disease", "start_pos": 216, "end_pos": 221}, {"label_type": "Anatomy", "start_pos": 5, "end_pos": 13}, {"label_type": "Anatomy", "start_pos": 58, "end_pos": 66}, {"label_type": "Anatomy", "start_pos": 99, "end_pos": 109}]}
{"originalText": "表_1)._表_1__夜间低血糖的时间分布_Tab_1___Distribution_of_nocturnal_hypoglycemia_according_to_time_period_时间_Time_例数_n_低血糖人数_Number_of_hypoglycemic_patients_低血糖次数_Number_hypoglycemia_events_22_:_00-___1_147_138_154_0_:_00-___1_147_122_152_2_:_00-___1_147_75_90_4_:_00-6_:_00_1_147_76_90_注:RR=1._72,_字2_=31._667,_P<0._01_三、_夜间低血糖发生率与晚餐后_3_h_血糖的关系_1._晚餐后_3_h_血糖与日平均血糖呈直线正相关_(_r=0._978),晚餐后_3_h_血糖值与低血糖发生次数关系_不明显(_r=_-0._509),平均发生(1._62_±1._01)次._2._晚餐后_3_h_血糖值与夜间低血糖发生率呈指数_曲线负相关(_r=_-0._955,", "entities": [{"label_type": "Test", "start_pos": 14, "end_pos": 16}, {"label_type": "Test", "start_pos": 108, "end_pos": 110}, {"label_type": "Test", "start_pos": 146, "end_pos": 148}, {"label_type": "Disease", "start_pos": 311, "end_pos": 316}, {"label_type": "Test", "start_pos": 320, "end_pos": 330}, {"label_type": "Test", "start_pos": 337, "end_pos": 347}, {"label_type": "Test", "start_pos": 348, "end_pos": 353}, {"label_type": "Test", "start_pos": 372, "end_pos": 382}, {"label_type": "Disease", "start_pos": 384, "end_pos": 387}, {"label_type": "Test", "start_pos": 435, "end_pos": 445}, {"label_type": "Disease", "start_pos": 447, "end_pos": 452}]}
{"originalText": "9c_75_±_7_2_型糖尿病_87(42_/_45)_57._91_±_7._30_25._40_±_3._02c_86._34_±_9._00c_0._89_±_0._09c___126_±_10_76_±_8_非肥胖_42(19_/_23)_58._19_±_7._41_22._97_±_1._40d_80._12_±_7._59d_0._87_±_0._11___123_±_11_74_±_8_肥胖_45(23_/_22)_57._64_±_7._26_27._66_±_2._27cf_92._16_±_5._75cf_0._91_±_0._07c___129_±_9c_78_±_7_组别_例数(男性_/_女性)_空腹血糖(mmol_/_L)_糖负荷后_2_h_血糖_(mmol_/_L)_HBA1C_(﹪)_空腹胰岛素_(mU_/_L)_ln(HOMA-IR)_正常糖耐量_89(44_/_45)_5._33_±_0._37_6._16_±_1._09_5._33_±_0._35_9._82_±_3._76_0._78_±_0._39_非肥胖_46(21_/_25)_5._25_±_0._33_6.", "entities": [{"label_type": "Disease", "start_pos": 10, "end_pos": 16}, {"label_type": "Test", "start_pos": 354, "end_pos": 359}, {"label_type": "Test", "start_pos": 316, "end_pos": 320}, {"label_type": "Test", "start_pos": 382, "end_pos": 389}, {"label_type": "Test", "start_pos": 364, "end_pos": 369}, {"label_type": "Test", "start_pos": 340, "end_pos": 342}]}
{"originalText": "长期使用不增加高乳酸血_症或乳酸酸中毒风险Ds-17].与其他降糖药物相比,_二甲双胍具有良好的成本一效益比[18](I级).如无_禁忌证,二甲双胍是治疗T2DM的首选药物和联合_治疗方案中的基础治疗药物,且应一直保留在糖尿_病治疗方案中._2.二甲双胍是否只是超重/llV,胖T2DM患者的_首选用药:回顾性和前瞻性临床研究[1争21]结果均显_示,--甲双胍在正常体重/超重/HE胖T2DM患者中_的疗效相当(I级).因此,体重不是能否使用二甲_双胍治疗的决定因素.无论对于超重/肥胖或体重_正常的患者,国内外主要糖尿病指南均推荐二甲双_胍为治疗T2DM的首选用药[3,22-24]._3.二甲双胍能否预防糖尿病:二甲双胍是第一_个被证明能预防糖尿病或延缓糖尿病发生的药物._能有效地降低糖尿病前期人群发生T2DM的风险,_且具有良好的耐受性和长期的有效性[z5_.但在我_国预防糖尿病尚不是二甲双胍的适应证._DPP是一项糖尿病预防计划的随机对照研_究[26_,该研究结果显示,强化生活方式干预和二甲_双胍(850_mg,2次/d)治疗,", "entities": [{"label_type": "SideEff", "start_pos": 7, "end_pos": 13}, {"label_type": "SideEff", "start_pos": 14, "end_pos": 19}, {"label_type": "Disease", "start_pos": 110, "end_pos": 114}, {"label_type": "Disease", "start_pos": 239, "end_pos": 244}, {"label_type": "Disease", "start_pos": 305, "end_pos": 308}, {"label_type": "Level", "start_pos": 322, "end_pos": 324}, {"label_type": "Level", "start_pos": 328, "end_pos": 330}, {"label_type": "Disease", "start_pos": 346, "end_pos": 351}, {"label_type": "Disease", "start_pos": 324, "end_pos": 327}, {"label_type": "Disease", "start_pos": 330, "end_pos": 333}, {"label_type": "Disease", "start_pos": 77, "end_pos": 81}, {"label_type": "Disease", "start_pos": 139, "end_pos": 143}, {"label_type": "Disease", "start_pos": 193, "end_pos": 197}, {"label_type": "Disease", "start_pos": 275, "end_pos": 279}, {"label_type": "Disease", "start_pos": 355, "end_pos": 359}, {"label_type": "Drug", "start_pos": 39, "end_pos": 43}, {"label_type": "Drug", "start_pos": 70, "end_pos": 74}, {"label_type": "Drug", "start_pos": 123, "end_pos": 127}, {"label_type": "Drug", "start_pos": 222, "end_pos": 227}, {"label_type": "Drug", "start_pos": 297, "end_pos": 301}, {"label_type": "Drug", "start_pos": 309, "end_pos": 313}, {"label_type": "Drug", "start_pos": 398, "end_pos": 402}, {"label_type": "Drug", "start_pos": 451, "end_pos": 456}, {"label_type": "Test", "start_pos": 214, "end_pos": 216}, {"label_type": "Drug", "start_pos": 267, "end_pos": 272}, {"label_type": "Disease", "start_pos": 131, "end_pos": 133}, {"label_type": "Test", "start_pos": 184, "end_pos": 186}, {"label_type": "Disease", "start_pos": 187, "end_pos": 189}, {"label_type": "Disease", "start_pos": 259, "end_pos": 262}, {"label_type": "Disease", "start_pos": 414, "end_pos": 417}, {"label_type": "Test", "start_pos": 245, "end_pos": 247}, {"label_type": "Test_Value", "start_pos": 248, "end_pos": 250}, {"label_type": "Disease", "start_pos": 392, "end_pos": 395}]}
{"originalText": "and_B10_levels_according_to_the_quartile_of_TPOAb_注:略语同表_1_和图_1_The_abbreviations_are_the_same_as_Tab_1_and_Fig_1;与_Q1_比较_vs_Q1,_aP<0._05;与_Q2_比较_vs_Q2,_bP<0._05_图_3__TGAb_四分位组间_CD19+CD24hiCD38hiBregs、CD8+CD28-Ts、CD19+CD24+CD27+Bregs、B10_的比较_Fig_3__Comparison_of_CD19+CD24hiCD38hiBregs,CD8+CD28-Ts,CD19+CD24+CD27+Bregs,and_B10_levels_according_to_the_quartile_of_TGAb_据._CD4+T_细胞是甲状腺细胞早期主要的浸润细胞,_CD8+T_细胞亚群中有一类_CD8+CD28-T_细胞,是一种_Ts,通过抑制抗原提呈细胞_CD40_信号通路而下调了_CD4+辅助细胞的表达[14]._本研究发现_HT_患者_CD8+_淋巴细胞较正常组显著降低,", "entities": [{"label_type": "Test", "start_pos": 44, "end_pos": 49}, {"label_type": "Test", "start_pos": 167, "end_pos": 171}, {"label_type": "Test", "start_pos": 363, "end_pos": 367}, {"label_type": "Anatomy", "start_pos": 380, "end_pos": 385}, {"label_type": "Anatomy", "start_pos": 411, "end_pos": 424}, {"label_type": "Anatomy", "start_pos": 429, "end_pos": 431}, {"label_type": "Anatomy", "start_pos": 457, "end_pos": 465}, {"label_type": "Disease", "start_pos": 480, "end_pos": 482}, {"label_type": "Anatomy", "start_pos": 4, "end_pos": 7}, {"label_type": "Anatomy", "start_pos": 178, "end_pos": 200}, {"label_type": "Anatomy", "start_pos": 201, "end_pos": 212}, {"label_type": "Anatomy", "start_pos": 213, "end_pos": 233}, {"label_type": "Anatomy", "start_pos": 234, "end_pos": 237}, {"label_type": "Anatomy", "start_pos": 263, "end_pos": 285}, {"label_type": "Anatomy", "start_pos": 286, "end_pos": 297}, {"label_type": "Anatomy", "start_pos": 298, "end_pos": 318}, {"label_type": "Anatomy", "start_pos": 323, "end_pos": 326}, {"label_type": "Test_Value", "start_pos": 499, "end_pos": 503}, {"label_type": "Anatomy", "start_pos": 371, "end_pos": 379}, {"label_type": "Anatomy", "start_pos": 396, "end_pos": 406}, {"label_type": "Anatomy", "start_pos": 436, "end_pos": 452}, {"label_type": "Anatomy", "start_pos": 486, "end_pos": 495}]}
{"originalText": "_and_diabetic_retinopathy._Logistic_regression_analysis_was_adopted_to_explore_the_risk_factors_for_DKD_in_inpatients_with_type_2_diabetes._Results_(1)_The_prevalence_of_albuminuria_in_patients_with_type_2_diabetes_mellitus_was_increased_with_declining_eGFR_(_P_<_0._05)_._(2)_The_prevalences_of_DKD_and_non-diabetic_renal_disease(NDRD)_in_patients_with_type_2_diabetes_mellitus_were_22._26%_and_8._92%_,_respectively._Compared_with_patients_with_NDRD,_patients_with_DKD_had_longer_diabetic_duration,", "entities": [{"label_type": "Test", "start_pos": 253, "end_pos": 257}, {"label_type": "Disease", "start_pos": 100, "end_pos": 103}, {"label_type": "Disease", "start_pos": 296, "end_pos": 299}, {"label_type": "Disease", "start_pos": 467, "end_pos": 470}]}
{"originalText": "体_重仅仅下降_4%_[36]_._体重降幅减少可能与试验前_4_周不当进_食有关[36]_,并不是与整个试验过程有关._另一个会影响到减_重程度的因素是每周限食的次数._与间断限食[10-11]_比较,隔日_限食减重速度更快[31-37]_._因为隔日限食研究中受试者每周限_食_3_~_4_天,而间断限食研究每周限食_1_~_2_天._通常,隔日限_食平均每周减重_0._75_kg,而间断限食平均每周减重_0._25_kg._2._减少内脏脂肪含量:不同的研究发现[32,34-37]_,经过_6_~_24_周隔日限食,内脏脂肪减少_4%_~_7%_._大多数研究中,体重_减少与内脏脂肪减少平行._例如,在_Varady_等[34]_的研究中,内_脏脂肪减少_6%_,体重减少_7%_._Bhutani_等[36]的研究有相似结_论,内脏脂肪减少_4%_,体重减少_4%_._然而,在上述的研究中,_内脏脂肪的评价±靠腰围,评价标准并没有量化,所以,这些研_究的结论受到局限._因此,应该采用更准确的技术,例如磁共_振成像,测量内脏脂肪实际质量的改变,", "entities": [{"label_type": "Test", "start_pos": 413, "end_pos": 415}, {"label_type": "Test", "start_pos": 18, "end_pos": 20}, {"label_type": "Test", "start_pos": 287, "end_pos": 289}, {"label_type": "Test", "start_pos": 338, "end_pos": 340}, {"label_type": "Test", "start_pos": 382, "end_pos": 384}, {"label_type": "Treatment", "start_pos": 87, "end_pos": 91}, {"label_type": "Treatment", "start_pos": 102, "end_pos": 107}, {"label_type": "Treatment", "start_pos": 125, "end_pos": 129}, {"label_type": "Treatment", "start_pos": 150, "end_pos": 154}, {"label_type": "Treatment", "start_pos": 173, "end_pos": 178}, {"label_type": "Treatment", "start_pos": 195, "end_pos": 199}, {"label_type": "Test", "start_pos": 221, "end_pos": 227}, {"label_type": "Treatment", "start_pos": 258, "end_pos": 262}, {"label_type": "Test", "start_pos": 263, "end_pos": 267}, {"label_type": "Test", "start_pos": 293, "end_pos": 297}, {"label_type": "Test", "start_pos": 326, "end_pos": 331}, {"label_type": "Test", "start_pos": 371, "end_pos": 375}, {"label_type": "Test", "start_pos": 459, "end_pos": 465}, {"label_type": "Duration", "start_pos": 250, "end_pos": 258}, {"label_type": "Test_Value", "start_pos": 290, "end_pos": 292}, {"label_type": "Test_Value", "start_pos": 297, "end_pos": 299}, {"label_type": "Anatomy", "start_pos": 404, "end_pos": 408}, {"label_type": "Treatment", "start_pos": 79, "end_pos": 81}, {"label_type": "Treatment", "start_pos": 137, "end_pos": 140}, {"label_type": "Test_Value", "start_pos": 267, "end_pos": 277}, {"label_type": "Test_Value", "start_pos": 331, "end_pos": 336}, {"label_type": "Test_Value", "start_pos": 340, "end_pos": 345}, {"label_type": "Test_Value", "start_pos": 375, "end_pos": 380}, {"label_type": "Test_Value", "start_pos": 384, "end_pos": 389}, {"label_type": "Test", "start_pos": 468, "end_pos": 476}]}
{"originalText": "传至四代开始做实_验._无氧培养液的配制:ECM_中通入含_5%_CO2、10%_H2和_85%_N2的混合气体饱和_30_min._接种至_60_mm_培养皿和_6_孔板的_HBVEC_以不同浓度葡萄糖(10、15_和_25_mmol_/_L)、FFA(50、100_和_200_μmol_/_L)在无氧培_养基孵育_72_h,或以_25_mmol_/_L_葡萄糖、200_μmol_/_L_FFA_分别刺激_24、48_和_72_h,以及高糖+高_FFA_联合_刺激_48_h_后,再低氧刺激_24_h,提取_60_mm_培养皿中_的总蛋白和_6_孔板中总_RNA._2._RT-PCR_检测_Hcdc14A_的_mRNA_表达:将_6_孔_板中的总_RNA_提取出来后测定总浓度及纯度后逆转_录为_cDNA,设计_Hcdc14A_引物,上游引物为_5'-CAT-_GAATTCATGGCAGCGGAGGGGGA-3'_(含有_EcoRI_酶_切位点),下游引物为_5'-CGGGTCGACTCAGAAGGC-_TTCCTTGGCAC-3(含有_SaII_酶切位点),", "entities": [{"label_type": "Reason", "start_pos": 221, "end_pos": 223}, {"label_type": "Reason", "start_pos": 244, "end_pos": 246}, {"label_type": "Test", "start_pos": 269, "end_pos": 272}, {"label_type": "Anatomy", "start_pos": 299, "end_pos": 313}, {"label_type": "Anatomy", "start_pos": 88, "end_pos": 93}, {"label_type": "Reason", "start_pos": 124, "end_pos": 127}, {"label_type": "Reason", "start_pos": 224, "end_pos": 229}, {"label_type": "Reason", "start_pos": 197, "end_pos": 200}]}
{"originalText": "线性上限为_33._3_mmol_/_L,试剂盒由中生北控生物科技股份公司提供._操作按试剂说明书严格进行,随批质控,由专业检验师_进行操作._2._血压测量:研究对象测量血压前_30_min_内禁止_吸烟或饮茶、咖啡,背靠静坐_15_min._采用经校正的汞_柱式血压计测量右侧肱动脉血压._收缩压读数取柯氏_音第玉时相,舒张压读数取柯氏音第吁时相._连续测_量_3_次,每次测量间隔_1_~_2_min,取其均值._3._血压分组:依据_2006_至_2007_年度收缩压、舒张_压及是否服用降压药物将观察对象分为正常血压组_(<120_/_80_mmHg,_1_mmHg_=_0._133_kPa)、正常高值组_(120_~_139_/_80_~_89_mmHg)、_高血压组_(≥_140_/_90_mmHg_或服用降压药物)._4._随访:于_2008_至_2009、2010_至_2011_年度对上_述开滦集团在职及离退休职工分别进行第_2_和第_3_次_健康体检._健康体检的调查内容、体检方法和项目、实_验室检查的方法和项目均同第一次体检,具体内容及_获取方法参阅本课题组已发表的文献[7,", "entities": [{"label_type": "Test", "start_pos": 147, "end_pos": 150}, {"label_type": "Test", "start_pos": 235, "end_pos": 238}, {"label_type": "Test", "start_pos": 162, "end_pos": 165}, {"label_type": "Test", "start_pos": 75, "end_pos": 77}, {"label_type": "Test", "start_pos": 86, "end_pos": 88}, {"label_type": "Test", "start_pos": 143, "end_pos": 145}, {"label_type": "Test", "start_pos": 213, "end_pos": 215}, {"label_type": "Test", "start_pos": 239, "end_pos": 243}, {"label_type": "Test_Value", "start_pos": 266, "end_pos": 280}, {"label_type": "Test_Value", "start_pos": 310, "end_pos": 334}, {"label_type": "Disease", "start_pos": 337, "end_pos": 340}, {"label_type": "Anatomy", "start_pos": 138, "end_pos": 143}]}
